ERBB2 and breast cancer: Different studies have shown that reaching a complete pathological response (pCR) after PST, particularly in patients with TNBC or HER2-positive tumors, is associated with a significant survival gain; thus, achieving a high rate of pCR has become a priority objective of the neoadjuvant systemic treatment of breast cancer, especially in the most unfavorable subgroups [6,7].